Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in MDA5 RP-ILD
NCT07486869Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in interstitial lung disease (ILD), sponsored by University of Miami. Started Jul 2026; status: recruiting.
02
Drugs
emapalumab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07486869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486869.